Prevents nausea and vomiting. ANDA 91342, held by Chartwell Molecular. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 91342 (Ondansetron Hydrochloride), held by Chartwell Molecular, was first approved by FDA on Jan 27, 2011, with 7 approved supplements and 0 published complete response letters.
Ondansetron oral solution is indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 initial and repeat courses of moderately emetogenic cancer chemotherapy radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron oral solution is also indicated for the prevention of postoperative nausea and/or vomiting.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 27, 2011 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron HydrochlorideEQ 4MG BASE/5ML · solution;oral | Ondansetron Hydrochloride | Rx |
| Jun 23, 2022 | Supplement 8Labeling · Standard review | Approved | None posted |
| Mar 14, 2018 | Supplement 5Labeling · Standard review | Approved | None posted |
| Mar 14, 2018 | Supplement 6Labeling · Standard review | Approved | None posted |
| Mar 3, 2016 | Supplement 4Manufacturing | Approved | None posted |
| Jan 14, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Oct 13, 2011 | Supplement 1Labeling | Approved | None posted |
| Jan 27, 2011 | Original application | Approved | None posted |
| Jan 27, 2011 | Supplement 27 | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters